Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A

NCT02930317 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Recombinant Factor VIII (50 IU/kg)
DRUG: Recombinant Factor VIII (On-demand treatment)

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.